Sugi Predict

Sugi Predict / Compounds / SCHEMBL1878446

SCHEMBL1878446

SCHEMBL1878446

COC(=O)c1c([N+](=O)[O-])cnn1C

nearest known ligand 0.57

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 1/20 0.57
▸ GAA P10253 1/20 0.54
▸ PKM P14618 2/20 0.54
▸ MEN1 O00255 5/20 0.53
▸ KMT2A Q03164 5/20 0.53
▸ CYP2C9 P11712 2/20 0.53
▸ CYP3A4 P08684 1/20 0.53
▸ POLB P06746 1/20 0.53
▸ KDM4E B2RXH2 1/20 0.53
▸ HPGD P15428 1/20 0.53
▸ CYP1A2 P05177 1/20 0.48
▸ CYP2D6 P10635 1/20 0.48
▸ CYP2C19 P33261 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28799897 0.89 TDP1 (0.48) TDP1GAAPKMMEN1KMT2A
SCHEMBL7457873 0.83 ALDH1A1 (0.54) TDP1GAAPKMMEN1KMT2A
SCHEMBL27895440 0.83 MEN1 (0.58) TDP1GAAPKMMEN1KMT2A
SCHEMBL31619713 0.83 TDP1 (0.44) TDP1GAAPKMMEN1KMT2A
SCHEMBL38658687 0.83 TDP1 (0.44) TDP1GAAPKMMEN1KMT2A
SCHEMBL12725198 0.82 TDP1 (0.44) TDP1GAAPKMMEN1KMT2A
SCHEMBL31319578 0.82 TDP1 (0.44) TDP1GAAPKMMEN1KMT2A
SCHEMBL16704245 0.81 MEN1 (0.57) TDP1GAAPKMMEN1KMT2A
SCHEMBL3998201 0.81 GAA (0.58) TDP1GAAPKMMEN1KMT2A
SCHEMBL570007 0.81 SMN1; SMN2 (0.57) TDP1GAAPKMMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12617799-B2 Pyrazolopyrimidinone compounds Orphagen Pharmaceuticals, Inc. (US) 2026-05-05 — — US disclosed
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-10-23 — — US disclosed
EP-4613773-A2 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-09-10 — — EP disclosed
US-12371430-B2 5-morpholin-4-yl-pyrazolo[4,3-b]pyridine derivatives MERCK PATENT GMBH (DE) 2025-07-29 — — US disclosed
EP-3731869-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-07-23 — — EP disclosed
US-20250100993-A1 2-SUBSTITUTED THIAZOLE HSD17B13 INHIBITORS AND USES THEREOF INIPHARM, INC. 2025-03-27 — — US disclosed
WO-2025038863-A1 INDOLE AND PYRROLOYPYRIDINE DERIVATIVES AS GPR17 MODULATORS BIOGEN MA INC. (US) 2025-02-20 — — WO disclosed
US-20250000985-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-01-02 — — US disclosed
US-12168057-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2024-12-17 — — US disclosed
EP-4469451-A1 2-SUBSTITUTED THIAZOLE HSD17B13 INHIBITORS AND USES THEREOF Inipharm, Inc. (US) 2024-12-04 — — EP disclosed
WO-2009026241-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-26 — — WO disclosed
EP-1970373-A1 ALICYCLIC HETEROCYCLIC COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2008-09-17 — — EP disclosed
EP-1956009-A1 AROMATIC COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2008-08-13 — — EP disclosed
WO-2008051047-A1 AMINOPYRAZOLE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF, AND COMPOSITION FOR PREVENTING OR TREATING ISCHEMIC DISEASES CONTAINING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2008-05-02 — — WO disclosed
EP-1847531-A1 PYRAZOLE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2007-10-24 — — EP disclosed
US-20070027166-A1 Pyrazolo pyrimidines useful as aurora kinase inhibitors SUNESIS PHARMACEUTICALS, INC. 2007-02-01 — — US disclosed
US-20070027166-A1 Pyrazolo pyrimidines useful as aurora kinase inhibitors SUNESIS PHARMACEUTICALS, INC. 2007-02-01 — — US disclosed
WO-2007013964-A1 PYRAZOLO PYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS SUNESIS PHARMACEUTICALS, INC. (US) 2007-02-01 — — WO disclosed
CN-1244576-C Compound (I) ASTRAZENECA AB (SE) 2006-03-08 — — CN disclosed
CN-1433411-A Compound (I) ASTRAZENECA AB (SE) 2003-07-30 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 TDP1 236/4885GAA 1234/4885PKM 1372/4885
US-20250100993-A1 2-SUBSTITUTED THIAZOLE HSD17B13 INHIBITORS AND USES THEREOF HSD17B1, HSD17B3, HSD17B13 TDP1 1273/4885GAA 1065/4885PKM 740/4885
US-20250000985-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 TDP1 236/4885GAA 1234/4885PKM 1372/4885
US-20070027166-A1 Pyrazolo pyrimidines useful as aurora kinase inhibitors AURKA, AURKB, AURKC TDP1 271/4885GAA 3181/4885PKM 758/4885
US-12168057-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 TDP1 236/4885GAA 1234/4885PKM 1372/4885
US-12617799-B2 Pyrazolopyrimidinone compounds CYP2B6, CBR1, CYP2D6 TDP1 3412/4885GAA 4024/4885PKM 2467/4885
US-12371430-B2 5-morpholin-4-yl-pyrazolo[4,3-b]pyridine derivatives ATR, CDK1, CDKN1A TDP1 100/4885GAA 3161/4885PKM 1197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.